drugset / Trial / NCT02139501

An Investigation of rhTPO With Different Frequencies in the Management of ITP

NCT02139501

RandomizedParallel-groupOpen-labelTreatment

Summary

The project was undertaking by Qilu Hospital of Shandong University and other well-known hospitals in China. In order to study the efficacy and safety of different dose and frequency Recombinant Human thrombopoietin in treating the primary immune thrombocytopenia (ITP)

Timeline

Start
2014-05
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject recombinant human thrombopoietin Protein / enzyme biologic 300 iu/kg Intravenous